Multi Drug Resistant Antibiotics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Veröffentlicht von: precision business insights
Veröffentlicht am: 22.02.2018 07:46
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Multi Drug Resistant Antibiotics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Pressekontakt:

Multi Drug Resistant Antibiotics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Market Outline: Multi-Drug Resistant Antibiotics Market
Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria.

Market Dynamics: Multi-Drug Resistant Antibiotics Market
Multi drug resistant antibiotics market is driven by the increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization’s initiatives and fundings are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the multi drug resistant antibiotics market over the forecast period. However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/multi-drug-resistant-antibiotics-market/#ulp-4H8Z4LpNMLEuOnnx



Market Scope: Multi Drug Resistant Antibiotics Market
Global multi drug resistant antibiotics market is segmented based on type of bacteria, disease and distribution channel
Based on type of bacteria, it is segmented into
• Multi Drug Resistant Enterococci
• Multi Drug Resistant Staphylococci
• Gram Negatives
• Others
Based on disease, it is segmented into
• Drug Resistant Tuberculosis
• Others
Based on distribution channel, it is segmented into
• Hospital Pharmacies
• Retail Pharmacies
• Others

Market Summary: Multi Drug Resistant Antibiotics Market
Emergence of antimicrobial resistance is a major concern, particularly in low and middle-income countries. Multi drug resistance antibiotics market is at growing stage owing to the availability of limited drug resistant antibiotics and there is a huge development need for the novel drugs. The market has many players who are actively participating in the development of the new treatment for multi drug resistant bacterial diseases. For instance, in February 2017, Discuva Ltd., drug discovery company expanded its collaboration with F. Hoffmann-La Roche AG in development of new antibiotic for the life-threatening infections caused by multi drug resistant bacteria and collaboration was originally initiated in February 2014. Furthermore, government and non-government organizations are funding in R&D and spreading awareness related to multi drug resistant antibiotics. Development of novel antibiotics such as plazomicin (in Phase III CL) by Achaogen, Cadazolid (in Phase III CL) by Acetlion Pharmaceuticals and many other companies and their expected commercialization in coming years may drive the market growth furthermore.

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/multi-drug-resistant-antibiotics-market/#ulp-c654SbFYO64MsOhu


Region Anaysis: Multi Drug Resistant Antibiotics Market
Geographically, multi drug resistant antibiotics market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America multi drug resistant market is expected to grow at significant rates owing to the factors such as growing awareness and increase in R&D activities in developing the novel drugs for multi drug resistant infections and well-established healthcare infrastructure. Europe market is driven by the increase in prevalence of the multi drug resistant infections and developed healthcare infrastructure. Asia Pacific multi drug resistant market is expected to grow at notable rates owing to low cost of R&D and expansion of the multinational companies into the developing countries such as India.

Market Participants: Multi Drug Resistant Antibiotics Market
Some of the players in Multi-Drug Resistant Antibiotics Market are F. Hoffmann-La Roche AG (Switzerland), Achaogen Inc. (U.S.), Acetlion Pharmaceuticals (Switzerland), Sanofi S.A (France), Johnson & Johnson Servieces Inc. (U.S.), Pfizer Inc. (U.S.), Otsuka Pharmaceutical (Japan), and Eli Lilly and Company (U.S.) to name a few.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/multi-drug-resistant-antibiotics-market/#ulp-14mlyhjMGhVjZqa3


Notable Market Developments: Multi Drug Resistant Antibiotics Market
• In August 2017, U.S. FDA approved The Medicines Company’s Vabomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria
• In May 2014, U.S. FDA approved Durata Therapeutic’s (acquired by Actavis) Dalvance (dalbavancin), new anti-bacterial drug for the methicillin-resistant Staphylococcus aureus (MRSA) infections


Key Features of the Report
• The report provides granular level information about The market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about The competitor’s overview, key findings and Their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by The industry
• The report tracks recent innovations, key developments and startup’s details that are working in The industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario


Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/multi-drug-resistant-antibiotics-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com




Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.